News

Under the deal terms, Celregen will gain the exclusive right for the development, production, and commercialisation of CLS001 to treat bullous keratopathy in the Greater China region, including

Daxxify for injection is a neuromuscular blocking agent and an acetylcholine release inhibitor, which is indicated to temporarily improve moderate to severe glabellar lines’ appearance related to corrugator

The investigational maternal vaccine candidate, hexavalent anti capsular polysaccharide (CPS) / cross reactive material 197 glycoconjugate (GBS6) is being developed to help prevent invasive GBS in new-borns. It

Recently, the company announced, EVX-B2, a new discovery project to develop a vaccine candidate for gonorrhea using EDEN, its artificial intelligence (AI) platform. In addition to UMass Chan’s

Forxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is administered orally once every day. It has shown efficacy in preventing and delaying cardiorenal disease, while protecting the

Located at the Research Triangle Park (RTP), the facility has nearly 3,300m2 of total gross floor area and will provide additional manufacturing capacity to produce autologous CAR T-cell

Spesolimab is a new selective antibody that inhibits the interleukin-36 receptor (IL-36R) signalling activation. It is claimed to be the first treatment option approved to treat GPP flares.

IPX203 is a new oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules that comprises extended-release (ER) coated beads and immediate-release (IR) granules. The company’s NDA submission is based on

The lipid-peptide analog, OK-101 comprises a 12 amino acid peptide sequence, an anchoring lipid domain, and a linker component. It has been developed using a new membrane-anchored peptide